title: Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations.
abstract: Interpretable and meaningful pharmacogenetic data are dependent on accurate characterization of phenotypes. High-quality reports are critical, and important clinical data must not be omitted. Adequate funding to fully support dedicated program personnel is essential to meet this requirement because an "employee-driven" network that funds its surveillance clinicians is likely to be more effective than a voluntary surveillance model in capturing both adequate numbers of cases and well-characterized clinical data for rigorous phenotyping.
authors.affiliation: Department of Paediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. bcarleton@popi.ubc.ca
authors.forename: B
authors.initials: B
authors.lastname: Carleton
mesh_terms: D000367:Age Factors; D002648:Child; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D010372:Pediatrics / Q000379:methods*; D010597:Pharmacogenetics / Q000379:methods*; D011358:Product Surveillance, Postmarketing / Q000379:methods*